$0 Co-Pay Program

Rubraca is available at $0 co-pay to 100% of commercially insured patients, regardless of income.


Text-based support

The Clovis4YOU text message support program is a personalized patient program with medication reminders, daily tips, emotional support, and more that can help you throughout treatment.


Share Your Story

You can make a difference for yourself and others by sharing your experiences and perspective.

Results of Rubraca treatment

In the clinical study, TRITON2:

  • 62 men with BRCA+ metastatic castration-resistant prostate cancer (mCRPC) who had received treatment with androgen receptor (AR)-directed therapy and chemotherapy were evaluated for response with Rubraca
  • All 62 men received the starting dose of Rubraca of 600 mg twice a day, for a total daily dose of 1200 mg (4 tablets)
  • All 62 men either had surgery or continued to take hormone therapy to lower testosterone during the study

This study enrolled many different types of patients, including those of different ages, races, inherited and acquired BRCA gene mutations, other gene mutations, and prior treatment experiences.

The TRITON2 study is still ongoing to confirm the clinical benefit of Rubraca. Rubraca was approved based on response rate and how long patients' responses lasted.

The benefits of Rubraca were measured by the following benchmarks:

Response rate: Percentage of patients whose tumors shrank with Rubraca by a meaningful amount*

Response Rate
27 out of 62 patients (44%) had their tumors shrink by a meaningful amount*

*Tumors had to have shrunk in size by at least 30% to be counted in these results.

Bottle image

Duration of response: How long the patient’s response to Rubraca lasted

Patients’ response to treatment with Rubraca ranged from 1.7 to more than 24.0 months. More than half (15 of 27) of patients who responded had a confirmed response to treatment lasting longer than 6 months. The clinical study is still ongoing.

How will I know if Rubraca is right for me?

Ask yourself all of these questions:

  • Have I tested positive for a BRCA gene mutation?
  • Have I been diagnosed with metastatic prostate cancer?
  • Have I been diagnosed with castration-resistant prostate cancer?
  • Have I been treated with androgen receptor-directed (AR) therapy and chemotherapy?

Talk to your doctor to see if Rubraca is right for you.

Remember, Rubraca works differently for everyone, so your individual results may vary.


What is Rubraca used for?

Rubraca® (rucaparib) tablets are a prescription medicine used in adults for the treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):

  • that has spread to other parts of the body, and
  • has a certain type of inherited (germline) or acquired (somatic) abnormal BRCA gene, and you have been treated with certain medicines for your cancer.

Rubraca was approved based on response rate and how long patients’ responses lasted. There are ongoing studies to confirm the clinical benefit of Rubraca. Your healthcare provider will perform a test to make sure Rubraca is right for you.

It is not known if Rubraca is safe and effective in children.

What Warnings should I know about Rubraca?

Rubraca tablets may cause serious side effects including bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have ovarian cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with Rubraca, although MDS or AML was not observed in men with prostate cancer during the clinical study. MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with Rubraca.

If you are a male with a female partner who is pregnant or able to become pregnant, effective birth control should be used during treatment and for 3 months after the last dose of Rubraca. Do not donate sperm during use and for 3 months after the last dose of Rubraca.

What other important information should I know about Rubraca?

Your healthcare provider will do blood tests before, and every month during treatment with Rubraca to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with Rubraca until your blood cell counts improve.

Avoid spending time in sunlight while on Rubraca since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

What are the side effects of Rubraca?

The most common side effects for men in Rubraca clinical studies were weakness/fatigue, nausea, decreased red blood cell count, changes in liver function tests, decreased appetite, constipation, rash, decreased platelet count, vomiting, and diarrhea.

What other medications might interact with Rubraca?

Rubraca can increase the amounts of other medications you may be taking which can increase the risk of side effects. Tell your healthcare provider about all of your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1‑800‑FDA‑1088 or www.fda.gov/medwatch. You may also report side effects to Clovis Oncology, Inc. at 1‑415‑409‑7220 (US toll) or 1‑844‑CLVS‑ONC (1‑844‑258‑7662; US toll-free).

Please see full Prescribing Information, including Patient Information, for additional Important Safety Information.